Pietro Tiraboschi

List of Publications by Year
in descending order

104	8,605	101384	46693
papers	citations	36 h-index	89 g-index

109	109	109	9060
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	0.7	18
2	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	3.7	27
3	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	2.8	21
4	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	3.0	4
5	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	1.1	2
6	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
7	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	1.5	1
8	PMCA-Based Detection of Prions in the Olfactory Mucosa of Patients With Sporadic Creutzfeldtâ€“Jakob Disease. Frontiers in Aging Neuroscience, 2022, 14, 848991.	1.7	4
9	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	1.7	1
10	Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB-SINdem). Neurological Sciences, 2022, 43, 4221-4229.	0.9	1
11	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology, 2022, 99, .	1.5	5
12	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.4	36
13	Automatic multispectral MRI segmentation of human hippocampal subfields: an evaluation of multicentric testâ€“retest reproducibility. Brain Structure and Function, 2021, 226, 137-150.	1.2	6
14	Cerebral amyloid angiopathy in a 51-year-old patient with embolization by dura mater extract and surgery for nasopharyngeal angiofibroma at age 17. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 142-143.	1.4	14
15	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	1.2	11
16	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	2.8	42
17	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	3.0	12
18	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	1.4	28

#	Article	IF	Citations
19	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	1.4	8
20	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	4.4	9
21	Italian consensus recommendations for a biomarkerâ€based aetiological diagnosis in mild cognitive impairment patients. European Journal of Neurology, 2020, 27, 475-483.	1.7	20
22	Incidence of dementia in the oldestâ€old and its relationship with age: The Monzino 80â€plus populationâ€based study. Alzheimer's and Dementia, 2020, 16, 472-481.	0.4	17
23	The Rise of the GRN C157KfsX97 Mutation in Southern Italy: Going Back to the Fall of the Western Roman Empire. Journal of Alzheimer's Disease, 2020, 78, 387-394.	1.2	1
24	Behavioral and Psychological Effects of Coronavirus Disease-19 Quarantine in Patients With Dementia. Frontiers in Psychiatry, 2020, 11, 578015.	1.3	157
25	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	0.9	106
26	Keeping People with Dementia or Mild Cognitive Impairment in Employment: A Literature Review on Its Determinants. International Journal of Environmental Research and Public Health, 2020, 17, 842.	1.2	20
27	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	2.8	19
28	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology, 2020, 94, 743-755.	1.5	365
29	The Impact of COVID-19 Quarantine on Patients With Dementia and Family Caregivers: A Nation-Wide Survey. Frontiers in Aging Neuroscience, 2020, 12, 625781.	1.7	85
30	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	1.1	26
31	Medical Informatics Platform (MIP): A Pilot Study Across Clinical Italian Cohorts. Frontiers in Neurology, 2020, 11, 1021.	1.1	10
32	Efficient RT-QuIC seeding activity for Î±-synuclein in olfactory mucosa samples of patients with Parkinsonâ€™s disease and multiple system atrophy. Translational Neurodegeneration, 2019, 8, 24.	3.6	106
33	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	4.9	128
34	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	2.1	33
35	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. Brain, 2019, 142, 1108-1120.	3.7	41
36	The role of molecular imaging in the frame of the revised dementia with Lewy body criteria. Clinical and Translational Imaging, 2019, 7, 83-98.	1.1	1

#	Article	IF	Citations
37	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	1.4	27
38	Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. Neurobiology of Aging, 2019, 76, 9-17.	1.5	23
39	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. NeuroImage, 2019, 188, 282-290.	2.1	16
40	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	1.5	47
41	Comparison of arterial spin labeling registration strategies in the multiâ€center GENetic frontotemporal dementia initiative (GENFI). Journal of Magnetic Resonance Imaging, 2018, 47, 131-140.	1.9	41
42	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiology of Aging, 2018, 62, 191-196.	1.5	151
43	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 2018, 62, 245.e9-245.e12.	1.5	40
44	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nature Communications, 2018, 9, 4273.	5.8	263
45	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the <scp>GENFI</scp> cohort: A crossâ€sectional diffusion tensor imaging study. Annals of Clinical and Translational Neurology, 2018, 5, 1025-1036.	1.7	39
46	The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. Alzheimer's Research and Therapy, 2017, 9, 27.	3.0	66
47	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain, 2017, 140, 1784-1791.	3.7	55
48	What is the best imaging technique in discriminating dementia with Lewy bodies from other dementias?. Geriatrics and Gerontology International, 2017, 17, 857-857.	0.7	0
49	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.5	2,805
50	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. NeuroImage: Clinical, 2017, 15, 171-180.	1.4	63
51	The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. Neurological Sciences, 2017, 38, 83-91.	0.9	11
52	¹²³Iâ€2Î²â€carbomethoxyâ€3Î²â€(4â€iodophenyl)â€Nâ€(3â€fluoropropyl) nortropane single photon emission computed tomography and ¹²³Iâ€metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study. Annals of Neurology, 2016, 80, 368-378.	2.8	42
53	Cognitive impairment in progressive supranuclear palsy-Richardsonâ€™s syndrome is related to white matter damage. Parkinsonism and Related Disorders, 2016, 31, 65-71.	1.1	17
54	Missense mutations in progranulin gene associated with frontotemporal lobar degeneration: study of pathogenetic features. Neurobiology of Aging, 2016, 38, 215.e1-215.e12.	1.5	16

#	Article	IF	Citations
55	Clinical trial design of serious gaming in mild cognitive impairment. Frontiers in Aging Neuroscience, 2015, 7, 26.	1.7	8
56	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurology, The, 2015, 14, 253-262.	4.9	432
57	Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy. Neurological Sciences, 2015, 36, 751-757.	0.9	9
58	Prevalence of dementia in the oldest old: The Monzino 80â€plus population based study. Alzheimer's and Dementia, 2015, 11, 258.	0.4	56
59	Clinicians' ability to diagnose dementia with Lewy bodies is not affected by Î²-amyloid load. Neurology, 2015, 84, 496-499.	1.5	44
60	Dementias. , 2015, , 183-195.		0
61	Absence of rapid eye movement sleep with hypnopompic visual hallucinations: A possible harbinger of dementia with Lewy bodies?. Sleep Medicine, 2013, 14, 377-379.	0.8	3
62	A promising rating scale for prion disease clinical research. Nature Reviews Neurology, 2013, 9, 366-367.	4.9	4
63	A case of convexity subarachnoid haemorrhage from intracranial hypotension treated with epidural blood patch. Neurological Sciences, 2012, 33, 715-716.	0.9	4
64	Updates on Somatoform Disorders (SFMD) in Parkinson's Disease and Dementia with Lewy Bodies and discussion of phenomenology. Journal of the Neurological Sciences, 2011, 310, 166-171.	0.3	43
65	Evaluating Voting Competence in Persons with Alzheimer Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-6.	1.1	6
66	A Population-based study of dementia in the oldest old: the Monzino 80-plus Study. BMC Neurology, 2011, 11, 54.	0.8	24
67	Fluctuating cognition and different cognitive and behavioural profiles in Parkinsonâ€™s disease with dementia: comparison of dementia with Lewy bodies and Alzheimerâ€™s disease. Journal of Neurology, 2010, 257, 1004-1011.	1.8	36
68	Ethical issues in end of life treatments for patients with dementia. European Journal of Neurology, 2010, 17, 774-779.	1.7	27
69	Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of NeuroInterventional Surgery, 2010, 2, 74-79.	2.0	65
70	Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage. Neurological Sciences, 2008, 29, 256-257.	0.9	8
71	Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies. Biological Psychiatry, 2008, 64, 850-855.	0.7	164
72	EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain, 2008, 131, 690-705.	3.7	292

#	Article	IF	Citations
73	Ethical questions in the treatment of subjects with dementia. Part I. Respecting autonomy: awareness, competence and behavioural disorders. Neurological Sciences, 2007, 28, 216-231.	0.9	26
74	What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?. Brain, 2006, 129, 729-735.	3.7	235
75	Smoking affects the phenotype of Alzheimer disease. Neurology, 2005, 64, 1301-1303.	1.5	30
76	Pergolide effect on cognitive functions in early-mild Parkinson?s disease. Journal of Neural Transmission, 2005, 112, 231-237.	1.4	38
77	The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology, 2004, 62, 1984-1989.	1.5	403
78	Alzheimer disease without neocortical neurofibrillary tangles. Neurology, 2004, 62, 1141-1147.	1.5	54
79	Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology, 2004, 62, 1977-1983.	1.5	192
80	Stem cells and neurology: cues for ethical reflections. Neurological Sciences, 2004, 25, 108-13.	0.9	1
81	Subthalamic deep brain stimulation improves time perception in Parkinsonâ€™s disease. NeuroReport, 2004, 15, 1071-1073.	0.6	52
82	Early and Widespread Cholinergic Losses Differentiate Dementia With Lewy Bodies From Alzheimer Disease. Archives of General Psychiatry, 2002, 59, 946.	13.8	155
83	Diagnostic Accuracy of Dementia With Lewy Bodies. Archives of Neurology, 2000, 57, 347.	4.9	127
84	Apolipoprotein E and Intronic Polymorphism of Presenilin 1 and Alpha-1-Antichymotrypsin in Alzheimerâ€™s Disease and Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2000, 11, 239-244.	0.7	26
85	E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimerâ€™s disease. Neurology, 2000, 54, 403-403.	1.5	38
86	Cholinergic dysfunction in diseases with Lewy bodies. Neurology, 2000, 54, 407-407.	1.5	316
87	The decline in synapses and cholinergic activity is asynchronous in Alzheimerâ€™s disease. Neurology, 2000, 55, 1278-1283.	1.5	113
88	Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease. Neurobiology of Aging, 2000, 21, 741-746.	1.5	47
89	Neurochemical Markers Do Not Correlate With Cognitive Decline in the Lewy Body Variant of Alzheimer Disease. Archives of Neurology, 1999, 56, 1458.	4.9	28
90	Disclosing the diagnosis to demented patients. Italian Journal of Neurological Sciences, 1997, 18, 25-28.	0.1	2

#	Article	IF	Citations
91	Ethical issues concerning research in patients with dementia. Italian Journal of Neurological Sciences, 1996, 17, 371-375.	0.1	2
92	Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease*. Clinical Pharmacology and Therapeutics, 1996, 60, 218-228.	2.3	60
93	Ethical issues in the care of patients with amyotrophic lateral sclerosis. Italian Journal of Neurological Sciences, 1995, 16, 328-332.	0.1	0
94	Multipleâ€Dose Pharmacokinetics and Safety of a Potential Memoryâ€Enhancing Compound, CL 275,838, in Healthy Male Volunteers. Journal of Clinical Pharmacology, 1994, 34, 748-753.	1.0	0
95	Conjugal Alzheimer's disease: Is there an increased risk in offspring?. Annals of Neurology, 1993, 34, 396-399.	2.8	16
96	Ethical considerations regarding overinvestigation in neurology. Italian Journal of Neurological Sciences, 1993, 14, 97-100.	0.1	0
97	Document on the persistent vegetative state by the SocietÃ Italiana di Neurologia (SIN) Working Group on Bioethics and Neurology. Italian Journal of Neurological Sciences, 1993, 14, 643-646.	0.1	0
98	Some comments on the Comitato Nazionale per la Bioetica document â€œDefinition and pronouncement of death in manâ€• Italian Journal of Neurological Sciences, 1993, 14, 647-650.	0.1	0
99	Singleâ€Dose Safety and Pharmacokinetics of a Potential Cognitionâ€Enhancing Compound, CL 275,838, in Healthy Volunteers. Journal of Clinical Pharmacology, 1993, 33, 845-850.	1.0	2
100	Rate of Progression and Prognostic Factors in Alzheimer's Disease: A Prospective Study. Journal of the American Geriatrics Society, 1993, 41, 45-49.	1.3	71
101	Longâ€term acetylâ€Lâ€carnitine treatment in Alzheimer's disease. Neurology, 1991, 41, 1726-1726.	1.5	206
102	Atypical features and prognosis of Wallenberg syndrome: Longitudinal study. Italian Journal of Neurological Sciences, 1988, 9, 547-550.	0.1	4
103	Developments in vertical tube evaporation. Desalination, 1985, 52, 135-143.	4.0	3
104	Five years experience in VTE industrial operations and their design improvements. Desalination, 1983, 45, 321-328.	4.0	1